Evidence map›Paper›PMID 39184870›Full record

ArticleOxford medical case reports2024

Sequential therapy for hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinoma: a case report and report of a new family pedigree.

Ichiro Tsuboi, Momoko Araki, Shuhei Yokoyama, Gen Tanaka, Kazutaka Mitani, Saori Yosioka, Yusuke Kobayashi, Hirochika Nakajima, Taichi Nagami, Kohei Ogawa and 2 more

Abstract readCase Reports
In one paragraph

Article in Oxford medical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ichiro TsuboiDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.ORCID https://orcid.org/0000-0002-3135-8262
Momoko ArakiDepartment of Clinical Genetics Unit, Shimane University Faculty of Medicine, Izumo, Japan.
Shuhei YokoyamaDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
Gen TanakaDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
Kazutaka MitaniDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
Saori YosiokaDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
Yusuke KobayashiDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
Hirochika NakajimaDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
Taichi NagamiDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
Kohei OgawaDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
Chiaki KoikeDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
Koichiro WadaDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare autosomal-dominant disorder caused by a heterozygous germline mutation in the fumarate hydratase (

Indexed as

FoundationOne Liquid CDxfumarate hydratasehereditary leiomyomatosis and renal cell cancerimmune checkpoint inhibitor

Identifiers

PMID39184870
PMCPMC11343826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.